ArticleCureus2025
The Relationship Between the Monocyte-to-High-Density Lipoprotein Cholesterol Ratio and Platelet Volume Indices With Diabetic Retinopathy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim This study aims to evaluate the roles of monocyte count-to-high-density lipoprotein (HDL) cholesterol ratio (MHR) and platelet volume indices (PVI) in predicting diabetic retinopathy (DR) in patients diagnosed with type 2 diabetes mellitus (DM) and to explore new methods for early prediction of retinopathy. Methods This prospective study included 120 patients aged over 18 years with type 2 DM diagnosed according to the American Diabetes Association criteria, along with a control group of 40 healthy individuals. Patients with type 2 DM were divided into three groups: 40 without retinopathy, 40 with non-proliferative diabetic retinopathy (NPDR), and 40 with proliferative diabetic retinopathy (PDR). Parameters such as complete blood count, PVI (mean platelet volume, platelet distribution width, plateletcrit, platelet large cell ratio), lipid profile, inflammatory markers (sedimentation rate, C-reactive protein), MHR, renal function tests, and glucose metabolism markers were analyzed alongside demographic, clinical, and laboratory data to assess their associations with DR in both patient and control groups. Results This study investigated the relationship between DR and hematological parameters (PVI, MHR). Hypertension, hyperlipidemia, and chronic kidney disease were common comorbidities. NPDR patients more frequently used metformin and dipeptidyl peptidase (DPP)-4 inhibitors, while PDR patients more often used insulin (p<0.05). Diabetic neuropathy and nephropathy were more prevalent in the PDR group. PDR patients had a significantly longer DM duration. Mean platelet volume (MPV) and platelet large cell ratio (PLCR) were higher in the PDR group. ROC analysis identified MHR (>11.9, 65% sensitivity, 35% specificity) and plateletcrit (PCT<0.29%, 61% sensitivity, 80% specificity) cut-offs for DR prediction. MHR's area under the curve (AUC) was greater than PCT's (p<0.05). MPV differed between PDR and NPDR, but MHR did not differ among DR groups or between DR/non-DR individuals. Glycosylated hemoglobin (HbA1c) and DM duration correlated positively with MHR, which also correlated with leukocyte count. HbA1c and glucose correlated with platelet distribution width (PDW). Each unit increase in DM duration increased MHR 1.13-fold, and each unit increase in HbA1c increased MHR 1.9-fold. Conclusions The duration of DM was significantly longer in patients with PDR compared to those with NPDR and those without retinopathy. MPV and PLCR levels were significantly higher in PDR patients than in NPDR patients. In evaluating the relationship between PVI and MHR for predicting diabetic retinopathy, significant cut-off values of MHR and PCT were found to be predictive indicators of diabetic retinopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.